Phaseline

Companies › MabQuest

MabQuest: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MAQ-001
Anti-PD-1 monoclonal antibody with alternative mechanism independent of PD-1/PD-L1 blockad
PDCD1Phase 1Advanced Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06514651MAQ-001Phase 1Advanced Solid TumorOncologyJun 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.